Institution
University of Milan
Education•Milan, Italy•
About: University of Milan is a education organization based out in Milan, Italy. It is known for research contribution in the topics: Population & Medicine. The organization has 58413 authors who have published 139784 publications receiving 4636354 citations. The organization is also known as: Università degli Studi di Milano & Statale.
Topics: Population, Medicine, Cancer, Blood pressure, Transplantation
Papers published on a yearly basis
Papers
More filters
••
TL;DR: The cumulative incidence of stent thrombosis 9 months after successful drug-eluting stent implantation in consecutive "real-world" patients was substantially higher than the rate reported in clinical trials.
Abstract: ContextTraditionally, stent thrombosis has been regarded as a complication
of percutaneous coronary interventions during the first 30 postprocedural
days. However, delayed endothelialization associated with the implantation
of drug-eluting stents may extend the risk of thrombosis beyond 30 days. Data
are limited regarding the risks and the impact of this phenomenon outside
clinical trials.ObjectiveTo evaluate the incidence, predictors, and clinical outcome of stent
thrombosis after implantation of sirolimus-eluting and paclitaxel-eluting
stents in routine clinical practice.Design, Setting, and PatientsProspective observational cohort study conducted at 1 academic hospital
and 2 community hospitals in Germany and Italy. A total of 2229 consecutive
patients underwent successful implantation of sirolimus-eluting (1062 patients,
1996 lesions, 2272 stents) or paclitaxel-eluting (1167 patients, 1801 lesions,
2223 stents) stents between April 2002 and January 2004.InterventionsImplantation of a drug-eluting stent (sirolimus or paclitaxel). All
patients were pretreated with ticlopidine or clopidogrel and aspirin. Aspirin
was continued indefinitely and clopidogrel or ticlopidine for at least 3 months
after sirolimus-eluting and for at least 6 months after paclitaxel-eluting
stent implantation.Main Outcome MeasuresSubacute thrombosis (from procedure end through 30 days), late thrombosis
(>30 days), and cumulative stent thrombosis.ResultsAt 9-month follow-up, 29 patients (1.3%) had stent thrombosis (9 [0.8%]
with sirolimus and 20 [1.7%] with paclitaxel; P = .09).
Fourteen patients had subacute thrombosis (0.6%) and 15 patients had late
thrombosis (0.7%). Among these 29 patients, 13 died (case fatality rate, 45%).
Independent predictors of stent thrombosis were premature antiplatelet therapy
discontinuation (hazard ratio [HR], 89.78; 95% CI, 29.90-269.60; P<.001), renal failure (HR, 6.49; 95% CI,
2.60-16.15; P<.001), bifurcation lesions (HR, 6.42;
95% CI, 2.93-14.07; P<.001), diabetes (HR, 3.71;
95% CI, 1.74-7.89; P = .001), and a lower
ejection fraction (HR, 1.09; 95% CI, 1.05-1.36; P<.001 for each 10% decrease).ConclusionsThe cumulative incidence of stent thrombosis 9 months after successful
drug-eluting stent implantation in consecutive “real-world” patients
was substantially higher than the rate reported in clinical trials. Premature
antiplatelet therapy discontinuation, renal failure, bifurcation lesions,
diabetes, and low ejection fraction were identified as predictors of thrombotic
events.
3,050 citations
••
University of Colorado Boulder1, Earth System Research Laboratory2, Met Office3, National Oceanic and Atmospheric Administration4, ETH Zurich5, University of Bern6, University of East Anglia7, Rovira i Virgili University8, University Corporation for Atmospheric Research9, South African Weather Service10, British Antarctic Survey11, University of Milan12, Norwegian Meteorological Institute13, University of Lisbon14, Environment Canada15, National Center for Atmospheric Research16
TL;DR: The Twentieth Century Reanalysis (20CR) dataset as discussed by the authors provides the first estimates of global tropospheric variability, and of the dataset's time-varying quality, from 1871 to the present at 6-hourly temporal and 2° spatial resolutions.
Abstract: The Twentieth Century Reanalysis (20CR) project is an international effort to produce a comprehensive global atmospheric circulation dataset spanning the twentieth century, assimilating only surface pressure reports and using observed monthly sea-surface temperature and sea-ice distributions as boundary conditions. It is chiefly motivated by a need to provide an observational dataset with quantified uncertainties for validations of climate model simulations of the twentieth century on all time-scales, with emphasis on the statistics of daily weather. It uses an Ensemble Kalman Filter data assimilation method with background ‘first guess’ fields supplied by an ensemble of forecasts from a global numerical weather prediction model. This directly yields a global analysis every 6 hours as the most likely state of the atmosphere, and also an uncertainty estimate of that analysis.
The 20CR dataset provides the first estimates of global tropospheric variability, and of the dataset's time-varying quality, from 1871 to the present at 6-hourly temporal and 2° spatial resolutions. Intercomparisons with independent radiosonde data indicate that the reanalyses are generally of high quality. The quality in the extratropical Northern Hemisphere throughout the century is similar to that of current three-day operational NWP forecasts. Intercomparisons over the second half-century of these surface-based reanalyses with other reanalyses that also make use of upper-air and satellite data are equally encouraging.
It is anticipated that the 20CR dataset will be a valuable resource to the climate research community for both model validations and diagnostic studies. Some surprising results are already evident. For instance, the long-term trends of indices representing the North Atlantic Oscillation, the tropical Pacific Walker Circulation, and the Pacific–North American pattern are weak or non-existent over the full period of record. The long-term trends of zonally averaged precipitation minus evaporation also differ in character from those in climate model simulations of the twentieth century. Copyright © 2011 Royal Meteorological Society and Crown Copyright.
3,043 citations
••
Valery L. Feigin1, Amanuel Alemu Abajobir2, Kalkidan Hassen Abate3, Foad Abd-Allah4 +267 more•Institutions (138)
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors (GBD) study provides such information but does not routinely aggregate results that are of interest to clinicians specialising in neurological conditions as discussed by the authors.
Abstract: Summary Background Comparable data on the global and country-specific burden of neurological disorders and their trends are crucial for health-care planning and resource allocation. The Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study provides such information but does not routinely aggregate results that are of interest to clinicians specialising in neurological conditions. In this systematic analysis, we quantified the global disease burden due to neurological disorders in 2015 and its relationship with country development level. Methods We estimated global and country-specific prevalence, mortality, disability-adjusted life-years (DALYs), years of life lost (YLLs), and years lived with disability (YLDs) for various neurological disorders that in the GBD classification have been previously spread across multiple disease groupings. The more inclusive grouping of neurological disorders included stroke, meningitis, encephalitis, tetanus, Alzheimer's disease and other dementias, Parkinson's disease, epilepsy, multiple sclerosis, motor neuron disease, migraine, tension-type headache, medication overuse headache, brain and nervous system cancers, and a residual category of other neurological disorders. We also analysed results based on the Socio-demographic Index (SDI), a compound measure of income per capita, education, and fertility, to identify patterns associated with development and how countries fare against expected outcomes relative to their level of development. Findings Neurological disorders ranked as the leading cause group of DALYs in 2015 (250·7 [95% uncertainty interval (UI) 229·1 to 274·7] million, comprising 10·2% of global DALYs) and the second-leading cause group of deaths (9·4 [9·1 to 9·7] million], comprising 16·8% of global deaths). The most prevalent neurological disorders were tension-type headache (1505·9 [UI 1337·3 to 1681·6 million cases]), migraine (958·8 [872·1 to 1055·6] million), medication overuse headache (58·5 [50·8 to 67·4 million]), and Alzheimer's disease and other dementias (46·0 [40·2 to 52·7 million]). Between 1990 and 2015, the number of deaths from neurological disorders increased by 36·7%, and the number of DALYs by 7·4%. These increases occurred despite decreases in age-standardised rates of death and DALYs of 26·1% and 29·7%, respectively; stroke and communicable neurological disorders were responsible for most of these decreases. Communicable neurological disorders were the largest cause of DALYs in countries with low SDI. Stroke rates were highest at middle levels of SDI and lowest at the highest SDI. Most of the changes in DALY rates of neurological disorders with development were driven by changes in YLLs. Interpretation Neurological disorders are an important cause of disability and death worldwide. Globally, the burden of neurological disorders has increased substantially over the past 25 years because of expanding population numbers and ageing, despite substantial decreases in mortality rates from stroke and communicable neurological disorders. The number of patients who will need care by clinicians with expertise in neurological conditions will continue to grow in coming decades. Policy makers and health-care providers should be aware of these trends to provide adequate services. Funding Bill & Melinda Gates Foundation.
2,995 citations
••
Johns Hopkins University1, University of Utah2, University of Rochester3, The Royal Marsden NHS Foundation Trust4, National Institutes of Health5, Stanford University6, Washington University in St. Louis7, Ontario Institute for Cancer Research8, University of Sydney9, St. Jude Medical Center10, University of Toronto11, Mayo Clinic12, American Society of Clinical Oncology13, University of Southern California14, North Carolina State University15, Indiana University16, University of Milan17, University of Michigan18
TL;DR: The Update Committee recommends that HER2 status (HER2 negative or positive) be determined in all patients with invasive breast cancer on the basis of one or more HER2 test results (negative, equivocal, or positive).
Abstract: Purpose
To update the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing in breast cancer to improve the accuracy of HER2 testing and its utility as a predictive marker in invasive breast cancer.
2,934 citations
••
Memorial Sloan Kettering Cancer Center1, Thomas Jefferson University2, Queen Mary University of London3, Netherlands Cancer Institute4, New York University5, University of Milan6, MedStar Georgetown University Hospital7, University of Chicago8, University of Paris-Sud9, Stanford University10, Technische Universität München11, Cleveland Clinic12, Mayo Clinic13, Icahn School of Medicine at Mount Sinai14, Yale University15, University of Navarra16, Sarah Cannon Research Institute17, Ottawa Hospital Research Institute18, Harvard University19, Genentech20, Foundation Medicine21, University of Virginia22
TL;DR: Treatment with atezolizumab resulted in a significantly improved RECIST v1.1 response rate, compared with a historical control overall response rate of 10%, and Exploratory analyses showed The Cancer Genome Atlas (TCGA) subtypes and mutation load to be independently predictive for response to atezolediazepine.
2,934 citations
Authors
Showing all 58902 results
Name | H-index | Papers | Citations |
---|---|---|---|
Yi Cui | 220 | 1015 | 199725 |
Peter J. Barnes | 194 | 1530 | 166618 |
Thomas C. Südhof | 191 | 653 | 118007 |
Charles A. Dinarello | 190 | 1058 | 139668 |
Alberto Mantovani | 183 | 1397 | 163826 |
John J.V. McMurray | 178 | 1389 | 184502 |
Giuseppe Remuzzi | 172 | 1226 | 160440 |
Russel J. Reiter | 169 | 1646 | 121010 |
Jean Louis Vincent | 161 | 1667 | 163721 |
Tobin J. Marks | 159 | 1621 | 111604 |
Tomas Hökfelt | 158 | 1033 | 95979 |
José Baselga | 156 | 707 | 122498 |
Naveed Sattar | 155 | 1326 | 116368 |
Silvia Franceschi | 155 | 1340 | 112504 |
Frederik Barkhof | 154 | 1449 | 104982 |